Jim Simons Cognition Therapeutics Inc Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 713,500 shares of CGTX stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

713,500

Previous 96,400 640.15%

Holding current value

$1.11 Million

Previous $29,000 3196.55%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$0.31 - $3.18 $191,301 - $1.96 Million	617,100 Added 640.15%	713,500 $956,000
Q2 2025 Aug 13, 2025	BUY	$0.24 - $0.45 $9,768 - $18,315	40,700 Added 73.07%	96,400 $29,000
Q1 2025 May 14, 2025	SELL	$0.39 - $0.85 $13,806 - $30,090	-35,400 Reduced 38.86%	55,700 $23,000
Q4 2024 Feb 13, 2025	BUY	$0.38 - $0.84 $912 - $2,016	2,400 Added 2.71%	91,100 $68,000
Q3 2024 Nov 13, 2024	SELL	$0.41 - $2.37 $417 - $2,412	-1,018 Reduced 1.13%	88,700 $41,000
Q2 2024 Aug 09, 2024	SELL	$1.66 - $2.62 $109,530 - $172,872	-65,982 Reduced 42.38%	89,718 $148,000
Q1 2024 May 13, 2024	BUY	$1.78 - $2.53 $255,786 - $363,561	143,700 Added 1197.5%	155,700 $283,000
Q4 2023 Feb 13, 2024	BUY	$0.96 - $2.42 $11,520 - $29,040	12,000 New	12,000 $22,000
Q1 2022 May 13, 2022	SELL	$2.41 - $6.9 $28,351 - $81,171	-11,764 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$5.1 - $12.98 $59,996 - $152,696	11,764 New	11,764 $74,000

Others Institutions Holding CGTX

# of Institutions

Shares Held

20.5M

Call Options Held

Put Options Held

View Full List

About COGNITION THERAPEUTICS INC

Ticker CGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,710,700
Market Cap $35.2M
Description
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...

More about CGTX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account